Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

U.S. contracts for vaccines

May 8, 2006 | A version of this story appeared in Volume 84, Issue 19

The Department of Health & Human Services has awarded five companies contracts totaling more than $1 billion to develop new technologies for producing influenza vaccines within the U.S. GlaxoSmithKline, MedImmune, Novartis, DynPort, and Solvay will work on cell-based vaccine manufacturing as an alternative to the chicken-egg-based method now employed. "Current capacity of egg-based influenza vaccine production is not sufficient to meet increased demands during an emergency," HHS Secretary Michael O. Leavitt says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.